A proteomic analysis of the endometrium in obese and overweight women with recurrent miscarriage: preliminary evidence for an endometrial defect by unknown
Metwally et al. Reproductive Biology and Endocrinology 2014, 12:75
http://www.rbej.com/content/12/1/75RESEARCH Open AccessA proteomic analysis of the endometrium in obese
and overweight women with recurrent miscarriage:
preliminary evidence for an endometrial defect
Mostafa Metwally1*, Rebecca Preece2, Jerry Thomas2, William Ledger3 and Tin Chiu Li4Abstract
Background: Overweight and obese women have been shown to have an increased risk of recurrent miscarriage
as well as other adverse reproductive outcomes, but it is yet unclear whether this is due to an effect on the
endometrium, embryo or both. The current study employs proteomic analysis to examine for a potential
endometrial defect in obese and overweight women with recurrent miscarriage.
Methods: Proteomic tissue analysis of 21 endometrial samples obtained In the midluteal phase from 16 women
with recurrent miscarriage (obese, n = 12 and lean, n = 4) and 5 fertile volunteers (Obese, n = 2 and Lean, n = 3).
Proteins were separated using 2-D gel electrophoresis and principle component analysis was used to quantitatively
compare protein expression between groups. Protein spots showing significantly altered expression were identified
using mass spectrometry.
Results: Obese and overweight recurrent miscarriage patients had a significantly increased endometrial expression
of haptoglobin compared to their lean counterparts (p = 0.01). These patients also displayed a significant increase
in endometrial expression of transthyretin (p = 0.04) and beta- globulin (p = 0.04). Principle Component Analysis
(PCA) of the studied groups also demonstrated that endometrial samples could be grouped based on differences
in the BMI, suggesting that obesity is an independent factor influencing endometrial protein expression.
Conclusions: These findings provide preliminary evidence for an alteration in the endometrial protein profile in
overweight/obese women with recurrent miscarriage mainly in the form of increased haptoglobin, an inflammatory
marker associated with obesity.
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There is growing evidence that an increase in body mass
index (BMI) is associated an increased risk of miscarriage
[1-3]. It is however unknown if this association is due to
an adverse effect on the embryo, endometrium or both.
The possibility of an endometrial defect was first pos-
tulated in a study of assisted conception cycles using
the oocyte donation model [4]. In an earlier study, we
attempted to identify the nature of any possible endomet-
rial defect by examining several markers of endometrial
function, including endometrial morphology, leukocyte* Correspondence: mmetwally@nhs.net
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unless otherwise stated.populations, leukaemia inhibitory factor and steroid
receptors using immunocytochemical staining, but
were unable to identify any clear effect on any of these
factors [5].
However there are a vast number of endometrial factors
involved in the implantation process and it is possible that
a specific endometrial defect was missed. To prospectively
examine all possible endometrial factors using immuno-
cytochemical staining or other molecular techniques could
be a time consuming and possibly unrevealing process, so
we postulated that by mapping the endometrial protein
profile around the time of implantation, potential target
proteins could be identified for further investigation.
The aim of this study was to determine firstly if over-
weight and obesity are associated with a change in theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The groups and numbers of patients used in the
study
Lean Obese Total
Control 3 2 5
Recurrent miscarriage 4 12 16
Total 7 14 21
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Endometrial samples from 16 consecutive women suffer-
ing from recurrent miscarriage and consenting to par-
ticipation were included as the study group. The study
was conducted at the recurrent miscarriage clinic of the
Jessop Wing, Royal Hallamshire Hospital, Sheffield, UK.
Recurrent miscarriage was defined as the occurrence of
three or more consecutive miscarriages at less than
20 weeks gestation. For each participant, the BMI was cal-
culated from the formula; weight (kg)/height2 (m2). A nor-
mal BMI (lean group) was defined as a BMI of 19.5 –
24.9 kg/m2 whilst a high BMI was defined as a BMI of
25 kg/m2 or more. The term “obese” was used to describe
all patients with a high BMI whether obese or overweight
for simplification. The control samples were obtained from
five fertile volunteers with no history of recurrent miscar-
riage or infertility. Women in the control group were not
receiving any form of hormonal therapy and none of them
were using an intrauterine contraceptive device. All par-
ticipants provided written consent to participate in the
study and the North of Sheffield Ethics Committee ap-
proved the study. Four groups of patients were therefore
compared in this study:
1- Obese recurrent miscarriage.
2- Lean recurrent miscarriage.
3- Obese control.
4- Lean Control.
Investigations for the recurrent miscarriage population
All the subjects underwent investigations according to
an established clinical protocol [6], including: prothrom-
botic studies and antiphospholipid antibody screening,
peripheral blood karyotyping, thyroid function tests,
thyroid antibodies, androgen profile (total serum testoster-
one, sex hormone binding globulin and free androgen
index), day 2 FSH, LH and oestradiol, transvaginal ultra-
sonography and hysterosalpingography.
Endometrial samples
Daily urine testing for Luteinising Hormone (LH) was
performed from the mid-follicular phase onwards until
the LH surge was detected. Seven to nine days follow-
ing the LH surge, an endometrial biopsy was obtained
with the use of a Pipelle sampler (Prodimed, France). The
biopsy was immediately frozen using liquid nitrogen and
stored for later processing. All participants used a barrier
method for contraception in the biopsy cycle.Proteomic analysis
Difference gel electrophoresis (DiGE)
Proteins were extracted from endometrial tissue first by
grinding in liquid nitrogen with a mortar and pestle,
then adding buffer (8 M urea, 5 mM magnesium acetate
and 2% CHAPS, 10 mM Tris–HCl, pH 8.5) and grinding
further on ice. Protease inhibitor cocktail (Roche complete
Mini) was added to the extracts before centrifuging at
15,000 rpm for 15–20 min. Supernatant protein content
was assayed using the Coomassie Plus Assay Kit (Pierce
Biotechnology). Aliquots of 50 μg of each extract were
combined to use as the internal standard in the DiGE
experiment. Proteins were labelled using the fluorescent
dyes, Cy3 and Cy5, developed for DIGE (GE Healthcare)
following the manufacturer’s recommended protocols.
Fifty micrograms of protein were labelled with 400 pmol
of amine reactive dyes, freshly dissolved in anhydrous
dimethyl formamide. Each of the protein extracts was
labelled with Cy5 and the pooled internal standard was
labelled with Cy3. The labelling reaction was incubated at
room temperature in the dark for 30 min and the reaction
was terminated by the addition of 10 nmol lysine.
Each Cy5-labeled protein sample (50 μg) was combined
with 50 μg of the Cy3-labeled internal standard, and then
made up to 450 μl with rehydration buffer (6 M urea, 2 M
thiourea, 4% CHAPS). Isoelectric focusing (IEF) was per-
formed using 24-cm Immobiline™ pH 3–10 strips (GE
Healthcare) and an EttanTM IPGphor 3 (GE Healthcare)
IEF system. Disulfide bonds were reduced by incubating
strips in 1.5 M Tris, pH 8.8, containing 6 M urea, 30%
glycerol, 2% SDS, and 1% dithioerythritol. Carbamido-
methylation was performed by incubating strips in 1.5 M
Tris, pH 8.8, containing 6 M urea, 30% glycerol, 2% SDS,
and 4% iodoacetamide. SDS-PAGE was performed using
an EttanTM DALT II (GE Healthcare) and 9-16% gradient
gels that were cast using an a2DEoptimizer (NextGen
Sciences Ltd). Fluorescent images were recorded using a
Molecular Imager FX with PDQuest™ software (Bio-Rad).
Image and statistical analysis
Four groups of patients were defined based on the char-
acteristics of weight (lean or obese) and reproductive
outcome (control or recurrent miscarriage) (Table 1). Two
additional groups were considered by combining all
control and all recurrent miscarriage patients (5 and 16
patients, respectively).
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four were of particular interest in this study – 1) lean
control versus lean miscarriage, 2) obese control versus
obese miscarriage, 3) all control versus all miscarriage,
and 4) lean miscarriage versus obese miscarriage.
Image and statistical analyses were performed using
Progenesis SameSpots software (version 3.0 2966.28996)
(Nonlinear Dynamics, Newcastle, UK). All images were
first warped to a manually selected reference gel. Follow-
ing warping, the images were grouped into the four
experimental groups and changes in spot volumes between
different groupings were calculated. All spots showing sig-
nificant normalized volume changes were manually vali-
dated in order to select genuine spots for further statistical
analysis. Principal Component Analysis (PCA) was per-
formed using only those spots whose fold changes were
statistically significant (p < 0.05).
Protein identification
To obtain enough protein in individual gel spots for
identification by mass spectrometry, preparative 2D gels
containing 1–1.5 mg protein were produced from pooled
samples. Protein spots were manually excised from the
Coomassie-stained 2D gels and digested overnight at
37°C with sequencing grade, modified porcine trypsin
(Promega) in 25 mM ammonium bicarbonate. Peptide
tandem mass spectra were obtained using a Bruker
ultraflex III MALDI-TOF/TOF mass spectrometer with
4-hydroxy-α-cyano-cinnamic acid (Sigma) as the matrix.
Proteins were identified by searching of the mass spectra
against the entire National Center for Biotechnology In-
formation Reference Sequence (release 36 with 9,655,479
sequences) using Mascot software (Matrix Science Ltd.,
London, UK). Search parameters included a maximum
of one missed cleavage, a peptide mass tolerance of
250 ppm, and a fragment mass tolerance of 0.5 Da.
Only peptide identifications with expectation values
above 0.01 are reported.
Finally a Medline literature search was performed with-
out restrictions on date and using a combination of the
following key words: proteomics, proteom*, endometrium,
endomet*, miscarriage and obesity.
Results
Demographics
The main demographic characteristics (age and BMI) of
the analysed patient groups and subgroups are sum-
marised in Table 2. The difference between mean BMI
values of obese and lean patients is significant (p = 0.01),
as expected, whereas none of the other differences were
significant. The number of previous miscarriages ranged
from 3–6 in the obese group and 3–5 in the non-obese
group (p > 0.05). The median number of miscarriages
was 3 in both groups.Twelve of the 16 endometrial samples from the recur-
rent miscarriage group were obtained from women with
unexplained recurrent miscarriage. The remaining four
samples (three of 12 samples from the obese miscarriage
group and one of four samples from the lean miscarriage
group) were from women with a diagnosis of antipho-
spholipid syndrome.
2D gel electrophoresis
The patient groups were compared by analysis of 2D
gels of proteins extracted from endometrial samples.
Representative 2D gels from all four patient groups are
shown in Figure 1. A total of 544 spots were identified.
Protein spots that differed significantly in expression
between the groups were used in the PCA to see whether
patient groups could be discriminated based on differ-
ences in protein expression observed in the 2D gels. The
gel spots used for each comparison are shown in Table 3.
Principle Component Analysis (PCA)
The results of PCA are summarised in combined plots
of the score and loading (biplots) [7]. In these biplots,
the coloured dots comprise the score plot, which shows
how gels are related to each other based on the inten-
sities of selected gel spots. The colour coding of dots
representing gels corresponds to known groupings into
which the gels were divided for the analysis. Gels with
similar protein expression profiles will be clustered together
in the score plot. The numbers in the biplot comprise the
loading plot. Each number represents a gel spot and its
position in the plot is a measure of its contribution to
the clustering of gels.
Control versus miscarriage
Biplots summarising comparisons of patients with recur-
rent miscarriage and controls are shown in Figure 2.
The top panel of Figure 2 shows the comparison of all
controls versus all miscarriages. These results suggest
that protein expression differences between the recurrent
miscarriage and control groups are not able to discrimin-
ate the two patient groups. The discrimination between
recurrent miscarriage and control groups is much better
when the obese and lean subgroups are analysed separ-
ately (bottom panels in Figure 2).
Lean versus obese
Biplots summarising comparisons of lean and obese
patients are shown in Figure 3. Obese and lean patient
groups are not well discriminated by the PCA (top
panel in Figure 3), but when samples are subdivided based
on the presence or absence of miscarriage subgroups show
a better discrimination (bottom left and right panels
in Fgure 3).
Table 2 The main demographic characteristics (age and BMI) of the analysed patient groups
All recurrent miscarriage n = 16 All controls n = 5 p
Age 35 ± 1.3 30 ± 2.1 0.07
BMI 26.3 ± 1.6 26.5 ± 2.8 1.0
Obese recurrent miscarriage n = 12 Obese controls n = 2
Age 33.0 ± 1.6 33.5 ± 2.5 1.0
BMI 28.3 ± 1.5 33.0 ± 7.0 0.3
Lean recurrent miscarriage n = 4 Lean controls n = 3
Age 37.2 ± 1.7 30.0 ± 3.0 0.06
BMI 20.0 ± 1.6 23.0 ± 1.0 0.13
Obese recurrent miscarriage n = 12 Lean recurrent miscarriage n = 4
Age 33.0 ± 1.6 37.2 ± 1.7 0.2
BMI 28.3 ± 1.5 20.0 ± 1.6 0.01
All values are mean ± SEM.
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Gel spots that were included in PCA were excised and
the protein in the spot was identified by mass spectrom-
etry of tryptic peptides. Mass spectra were matched to
protein sequences using Mascot software, which gives
a probability-based score that indicates the likelihood
that the match is true. The proteins identified and the
corresponding Mascot scores are shown in Table 3.
Also shown are the fold differences in intensity for
each spot, the statistical significance (ANOVA) of each
measured difference, and the direction of the dif-Lean control 
lortnocesebO
Figure 1 Representative 2-D gel analyses of the four patient groups.ference (left-most column). All of the proteins identi-
fied are serum components. Detection of the same
protein in different regions of the gel suggests the
presence of isoforms, post-translational modification,
and/or degradation.
Haptoglobin alpha chain (spot 1163) appears to con-
tribute to the discrimination observed in all four of the
comparisons of interest in this study; the levels of this
protein are lower in the miscarriage groups compared
to control groups, but higher in the obese miscarriage
group compared to the lean miscarriage group.Lean recurrent miscarriage 
egairracsimtnerruceresebO
Table 3 Gel spots used in PCA and protein identities
Spot number Fold change Direction of change ANOVA (p) Protein identification Mascot score
Recurrent miscarriage versus control – All subjects
1163 2.3 < 0.547 Haptoglobin alpha chain 109
1172 2.2 < 0.547 Haptoglobin alpha chain *
868 1.8 > 0.547
254 1.8 > 0.547 Transferrin 547
252 1.8 > 0.547 Transferrin 693
1183 1.6 < 0.547 Haptoglobin alpha chain *
119 1.6 > 0.547 Serum albumin 162
635 1.6 < 0.547 Haptoglobin beta chain 160
3 1.5 < 0.547 α-1-Antitrypsin 684
489 1.5 > 0.547
Recurrent miscarriage versus control – Obese only
263 5.3 > 0.004
1172 2.5 < 0.017 Haptoglobin alpha chain
620 1.9 < 0.025
1163 2.0 < 0.036 Haptoglobin alpha chain 160
152 1.8 > 0.037
Recurrent miscarriage versus control – Lean only
1163 4.1 < 0.026 Haptoglobin alpha chain 109
901 2.7 > 0.014
1183 2.2 < 0.036 Haptoglobin alpha chain *
83 2.0 < 0.030
252 2.0 > 0.007 Transferrin 693
601 1.9 < 0.048 Hemoglobin beta subunit 522
856 1.9 < 0.020 Hemoglobin beta subunit 167
91 1.6 < 0.049
561 1.6 < 0.002
401 1.6 > 0.039
800 1.6 < 0.020
184 1.5 > 0.016
125 1.5 < 0.039
937 1.5 > 0.023
659 1.5 < 0.038
887 1.5 > 0.006
760 1.4 > 0.019
1009 1.3 > 0.039
Obese versus lean – Recurrent miscarriage only
1163 2.0 > 0.014 Haptoglobin alpha chain 109
1044 1.8 < 0.010
930 1.6 > 0.037
1301 1.5 > 0.040 Transthyretin (Prealbumin) 158
601 1.5 > 0.045 Hemoglobin beta subunit 522
*Identity inferred from position in 2D gel indicating the same molecular weight and nearly the same isoelectric point as spot 1163.
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Figure 2 PCA biplots of recurrent miscarriage versus control patient groups. 2D gels from the recurrent miscarriage groups are represented
by orange dots and from control groups by purple dots in the score plot. Numbers in the loading plot indicate gel spots with statistically significant
differences in intensity between groups, which were used for the PCA.
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To better estimate the false discovery rate and address the
multiple-testing problem [8], q-values [9] were calculated
for each spot. The calculated q-values (Table 3) suggest
that about half of the spots determined to have significant
fold changes with p < 0.05 could be false positives. The
suggested number of samples that would be required in a
future study to achieve a desired power of 0.8 [8] for the
four group comparisons of interest would be 64 for lean
versus obese recurrent miscarriage, 30 for lean versusrecurrent miscarriage obese, 120 for all control versus
recurrent miscarriage, and 10 for lean control versus
recurrent miscarriage.
Discussion
Differential expression of the endometrial protein profile
in the different phases of the menstrual cycle has been
described by Rai et al. [10] and since then the use of
endometrial proteomics has continued albeit mainly
























Figure 3 PCA biplots of obese versus lean groups. 2D gels from the obese groups are represented by yellow dots and from lean groups by blue
dots in the score plot. Numbers in the loading plot indicate gel spots with statistically significant differences in intensity between groups, which were
used for the PCA. Plots of all obese versus all lean (top) and obese control versus lean control (bottom right) are included for completeness.
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this pilot study is the first to use proteomic analysis to
study the endometrial protein expression around the
implantation period in women with recurrent miscarriage
and to use this technique to investigate the possible effect
of increased BMI on the endometrium.
When examining the whole population (obese and lean),
the first finding of this study was that PCA had a poor
ability to discriminate the samples. Although this may
be due to the absence of a distinctive difference inendometrial protein expression between miscarriage and
control samples, it may also be due the presence of con-
founding factors that led to heterogeneity of the samples.
We hypothesised that the presence of an increased
BMI may be one such confounding factor and repeated
the analysis after exclusion of samples from patients with
an increased BMI. The analysis was repeated (Figure 2)
and PCA then showed good discrimination of recurrent
miscarriage and control samples indicating that an in-
creased BMI may indeed have acted as a confounding
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control samples could also be discriminated using PCA,
further providing evidence for a difference in endometrial
protein expression (Figure 3).
Haptoglobin alpha chain (spot 1163) appears to contrib-
ute to the discrimination observed in all the comparisons
of interest. The endometrial concentrations of this protein
are lower in the miscarriage groups compared to control
groups, but higher in the obese miscarriage group com-
pared to the lean miscarriage group. Haptoglobin there-
fore seems to be affected both by the presence of
recurrent miscarriage as well as by increased BMI, as
both conditions seem to have an opposite effect on
haptoglobin concentrations. Other proteins that were
significantly increased in the obese miscarriage group
were transthyretin (pre-albumin), and beta globin.
Haptoglobin is a glycoprotein synthesised in the liver.
Its primary function is to bind excess haemoglobin thus
protecting the kidneys in cases of intravascular haemolysis
[16]. However haptoglobin has several other functions
that may be relevant to both implantation and obesity.
Firstly haptoglobin is an important component of the
body’s response to inflammatory conditions [17-19]. One
such inflammatory condition is obesity, where an increase
in the central fat compartment leads to a state of relative
hypoxia in the adipocytes and a release of a number of
inflammatory markers including haptoglobin. Indeed hap-
toglobin concentrations have been shown to positively
increase in proportion to the severity of obesity [17,18].
It is therefore possible that haptoglobin is a marker of
an ongoing inflammatory reaction in the endometrial
lining of obese women with recurrent miscarriage, which
may explain their adverse reproductive outcomes.
Secondly haptoglobin is produced by the endometrium
[20] and has been shown in several animal studies to be
expressed in increasing amounts in the peri implantation
period and is an important component of the extra em-
bryonic matrix [16,19,21]. This increase in endometrial
haptoglobin around the time of implantation may play a
role in modulating the maternal reaction to the implanting
blastocyst [16,19].
The haptoglobin molecule is also known to display
genetic polymorphism where some genotypes have been
shown to be associated with better reproductive outcomes
compared to others [22]. So although obese miscarriage
women showed an increased expression of endometrial
haptoglobin, it is possible that haptoglobin in this case is
of a different genotype that results in a less favourable
pregnancy outcome. Future studies should analyse the
specific genotype of the haptoglobin molecule using
techniques such as Polymerase chain reaction and gel
electrophoresis [23].
Obese recurrent miscarriage samples were also associated
with a significantly increased expression of transthyretinand beta globin, both of which are common intravascular
products normally found in relative abundance in tis-
sue. However, their increased expression in the obese
miscarriage cohort may indicate some form of vascular
or endothelial dysfunction in these women. Indeed vascu-
lar dysfunction is a characteristic of chronic inflammatory
conditions such as obesity [24,25].
There are several mechanisms that could support the
hypothesis of a local vascular dysfunction in obese women.
Firstly hyperleptinaemia has been linked to the occurrence
of vascular dysfunction possibly through dysregulation of
endothelial nitric oxide [24,25]. Similarly the production of
cytokines has also been linked to vascular dysfunction [26].
Finally haptoglobin has been found to have an important
role in angiogenesis and vascular dysfunction in chronic
inflammatory conditions and this may be more common
with certain haptoglobin genotypes [27,28].
It would be interesting to know whether obesity pro-
duces any structural changes in fertile women as well
as woman with miscarriage and therefore a comparison
between obese and non-obese controls would have been
ideal. However due to relatively small numbers of the
control subgroups, this was not practically possible, but
should be addressed in future studies.
A possible confounding factor in this study is the pres-
ence of four samples from women with antiphospholipid
syndrome which may act as a potential source of bias.
Therefore careful consideration was given as to whether
these samples should be excluded from the analysis.
However the potential effect of antiphospholipid anti-
bodies on pro inflammatory mediators such as tumour
necrosis factor α (TNFα) [29] has only been demon-
strated in animal studies and recent human studies have
been unable to demonstrate similar findings [30]. So
even though we cannot rule out a possible confounding
effect, it is highly unlikely particularly in view of the
small number of women with this condition relative to
the whole population.
It was not possible to employ a second analysis tech-
nique to confirm the results since all the tissue was
consumed in the process of protein extraction and ana-
lysis and we were unable to conserve tissue for further
analysis. Endometrial samples in this study were obtained
in an out-patient setting which results in a relatively small
amount of tissue being retrieved and repetition of sampling
more than once to obtain more tissue would not have been
acceptable due to the associated patient discomfort.
A general limitation of proteomic analysis is that only
abundant proteins can be detected. It is possible that other
proteins that are relevant to the process of implantation
were missed in this analysis either because they were
expressed in small amounts or had a molecular weight
below the level of detection using our particular method
of analysis.
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approaching the same research question in future stud-
ies. Validation of changes in protein expression levels
observed with a 2D gel-based approach could be carried
out using orthogonal techniques such as Western blotting
[31] or a targeted proteomic approach using stable
isotope-labeled peptides and multiple reaction monitoring
[32]. While the former approach is feasible when appro-
priate antibodies are available, the latter would require a
considerable amount of effort and expense. The problem
of abundant proteins in proteomic studies, especially of
serum, can be addressed by antibody-based depletion, for
example with the Agilent MARS columns. However, a
major drawback of using a depletion method is the poten-
tial loss of important markers through their non-specific
binding to depleted proteins, especially albumin [33].
Other possible approaches include micro arrays and
genomic or metabolomic analysis. It is yet unclear whether
these technologies would offer an advantage over proteo-
mics when trying to answer the current question.
We would like to emphasise that the results of this
study are mainly limited to women with mild obesity;
further studies would be needed to examine the effect of
more severe forms of obesity on the protein profile.
However this may prove difficult since patients with severe
degrees of obesity may present more with problems related
to infertility rather than recurrent miscarriage. Neverthe-
less, it may be possible to achieve the necessary numbers in
these subgroups in the context of a large multicentre study.
Finally, as there were no previous similar studies, we
had no guidance by which to perform a sample size
calculation when designing this study. Our findings
however have now provided data regarding the necessary
sample size for future studies as stated above. Larger
studies are now needed to confirm our findings.Conclusions
In conclusion the results of this study suggest that Obese
and overweight women with recurrent miscarriage have an
altered endometrial protein profile that is mainly related
to changes in haptoglobin expression. This may provide
evidence for an ongoing endometrial inflammatory reac-
tion in the endometrial linings of obese women and may
contribute to their higher risk of miscarriage.Competing interests
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